Posttransplant depression has been linked to increased risk for adverse outcomes in lung transplant patients. Maintaining target serum immunosuppressant levels is also essential for optimal lung transplant clinical outcome and may be a crucial predictor of outcomes. Because depression could affect medication nonadherence, resulting in out-of-range immunosuppressant levels, we examined the relationship between posttransplant depression, immunosuppressant medication trough level variability, indexed by out-of-range values on clinical outcomes and coefficient of variability, and clinical outcomes.
Method
A consecutive series of 236 lung transplant recipients completed the Center for Epidemiological Studies-Depression two-month posttransplant. Immunosuppressant trough levels (i.e., tacrolimus or cyclosporine) within the range of individualized immunosuppressant targets were obtained at three-, six-, nine-month follow-up clinic visits. Clinical outcomes including hospitalizations and mortality were obtained from medical records.
Results
Fourteen percent of patients were classified as depressed (Center for Epidemiological Studies-Depression ≥16), 144 (61%) of patients had at least 25% out-of-range immunosuppressant values, and the average coefficient of variability was 36%. Over a median of 2.6 years (interquartile range = 1.2), 32 participants died (14%) and 144 (61%) had at least one unplanned, transplant-related hospitalization. Both depression (hazard ratio = 1.45 (1.19, 1.76), p < . 01) and immunosuppressant variation (immunosuppressant out-of-range: hazard ratio = 1.41 (1.10, 1.81), p < .01) independently predicted more frequent hospitalizations and higher mortality.
Conclusions
Early posttransplant depression was associated with significantly worse clinical outcomes. While immunosuppressant level variability is also related to adverse outcomes, such variability does not account for increased risk observed with depression.
TrulockEPEdwardsLBTaylorDO, et al.
Registry of the International Society for Heart and Lung Transplantation: Twenty-second official adult lung and heart-lung transplant report—2005. J Heart Lung Transplant2005;
24: 956–967.
3.
ParekhPIBlumenthalJABabyakMA, et al.
Psychiatric disorder and quality of life in patients awaiting lung transplantation. Chest2003;
124: 1682–1688.
4.
DewMADiMartiniAFDeVito DabbsAJ, et al.
Onset and risk factors for anxiety and depression during the first 2 years after lung transplantation. Gen Hosp Psychiatry2012;
34: 127–138.
5.
SmithPJBlumenthalJASnyderLD, et al.
Depressive symptoms and early mortality following lung transplantation: a pilot study. Clin Transplant2017;
31: e12874.
6.
RosenbergerEMDiMartiniAFDeVito DabbsAJ, et al.
Psychiatric predictors of long-term transplant-related outcomes in lung transplant recipients. Transplantation2016;
100: 239–247.
7.
SmithPJBlumenthalJATrulockEP, et al.
Psychosocial predictors of mortality following lung transplantation. Am J Transplant2016;
16: 271–277.
8.
DewMADimartiniAFDe Vito DabbsA, et al.
Adherence to the medical regimen during the first two years after lung transplantation. Transplantation2008;
85: 193–202.
9.
CourtwrightAMSalomonSLehmannLS, et al.
The effect of pretransplant depression and anxiety on survival following lung transplant: a meta-analysis. Psychosomatics2016;
57: 238–245.
10.
ButlerJARoderickPMulleeM, et al.
Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation2004;
77: 769–776.
11.
PinskyBWTakemotoSKLentineKL, et al.
Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant2009;
9: 2597–2606.
12.
PrendergastMBGastonRS.Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol2010;
5: 1305–1311.
13.
CastleberryAWBishawiMWorniM, et al.
Medication nonadherence after lung transplantation in adult recipients. Ann Thorac Surg2017;
103: 274–280.
14.
DewMADiMartiniAFDe Vito DabbsA, et al.
Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation2007;
83: 858–873.
15.
MattheesBJAnantachotiPKreitzerMJ, et al.
Use of complementary therapies, adherence, and quality of life in lung transplant recipients. Heart Lung2001;
30: 258–268.
16.
BosmaOHVermeulenKMVerschuurenEA, et al.
Adherence to immunosuppression in adult lung transplant recipients: prevalence and risk factors. J Heart Lung Transplant2011;
30: 1275–1280.
17.
HuLLinglerJHSereikaSM, et al.
Nonadherence to the medical regimen after lung transplantation: a systematic review. Heart Lung2017;
46: 178–186.
18.
KnoopCEstenneM.Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med2006;
27: 521–533.
19.
SerperMPatzerREReesePP, et al.
Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients. Liver Transpl2015;
21: 22–28.
20.
PatzerRESerperMReesePP, et al.
Medication understanding, non-adherence, and clinical outcomes among adult kidney transplant recipients. Clin Transpl2016;
30: 1294–1305.
21.
CarneyRMFreedlandKEEisenSA, et al.
Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol1995;
14: 88–90.
22.
GehiAHaasDPipkinS, et al.
Depression and medication adherence in outpatients with coronary heart disease. Arch Intern Med2005;
165: 2508.
23.
DiMatteoMRLepperHSCroghanTW.Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med2000;
160: 2101–2107.
24.
GrayALMulvihillMSHartwigMG.Lung transplantation at Duke. J Thorac Dis2016;
8: E185–E196.
25.
RadloffLS.The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas1977;
1: 385–401.
26.
LewinsohnPMSeeleyJRRobertsRE, et al.
Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging1997;
12: 277–287.
27.
LoiselleKAGutierrez-ColinaAMEatonCK, et al.
Longitudinal stability of medication adherence among adolescent solid organ transplant recipients. Pediatr Transpl2015;
19: 428–435.
28.
ChisholmMA.Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs2002;
62: 567–575.
29.
KahanBDKeownPLevyGA, et al.
Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther2002;
24: 330–350, discussion 329.
30.
FlippinMSCanterCEBalzerDT.Increased morbidity and high variability of cyclosporine levels in pediatric heart transplant recipients. J Heart Lung Transpl2000;
19: 343–349.
31.
FredericksEMDore-StitesDWellA, et al.
Assessment of transition readiness skills and adherence in pediatric liver transplant recipients. Pediatr Transpl2010;
14: 944–953.
32.
Schäfer-KellerPSteigerJBockA, et al.
Diagnostic accuracy of measurement methods to assess non-adherence to immunosuppressive drugs in kidney transplant recipients. Am J Transpl2008;
8: 616–626.
33.
HsiauMFernandezHEGjertsonD, et al.
Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. Transplantation2011;
92: 918–922.
34.
GleissAOberbauerRHeinzeG.An unjustified benefit: immortal time bias in the analysis of time-dependent events. Transpl Int2018;
31: 125–130.
35.
CohenLLittlefieldCKellyP, et al.
Predictors of quality of life and adjustment after lung transplantation. Chest1998;
113: 633–644.
36.
SmithPJBlumenthalJACarneyRM, et al.
Neurobehavioral functioning and survival following lung transplantation. Chest2014;
145: 604–611.
37.
EvonDMBurkerEJGalankoJA, et al.
Depressive symptoms and mortality in lung transplant. Clin Transpl2010;
24: E201–E206.
38.
VermeulenKMTenVergertEMVerschuurenEAM, et al.
Pre-transplant quality of life does not predict survival after lung transplantation. J Heart Lung Transpl2008;
27: 623–627.
39.
SquierHCRiesALKaplanRM, et al.
Quality of well-being predicts survival in lung transplantation candidates. Am J Respir Crit Care Med1995;
152: 2032–2036.
40.
DewMARosenbergerEMMyaskovskyL, et al.
Depression and anxiety as risk factors for morbidity and mortality after organ transplantation: a systematic review and meta-analysis. Transplantation2015;
100: 988–1003.
41.
ZipfelSSchneiderAWildB, et al. Effect of depressive symptoms on survival after heart transplantation. Psychosom Med 64: 740–747.
42.
JonasBSMussolinoME. Symptoms of depression as a prospective risk factor for stroke. Psychosom Med 62: 463–471.
43.
DewMARothLHThompsonME, et al.
Medical compliance and its predictors in the first year after heart transplantation. J Heart Lung Transpl1996;
15: 631–645.
44.
DiMatteoMR.Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care2004;
42: 200–209.
45.
De BleserLDobbelsFBerbenL, et al.
The spectrum of nonadherence with medication in heart, liver, and lung tranplant patients assessed in various ways. Transpl Int2011;
24: 882–891.
46.
ScheelJReberSStoesselL, et al.
Patient-reported non-adherence and immunosuppressant trough levels are associated with rejection after renal transplantation. BMC Nephrol2017;
18: 107.
47.
RodrigoESegundoDSFernández-FresnedoG, et al.
Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. Transplantation2016;
100: 2479–2485.
48.
ShukerNvan GelderTHesselinkDA.Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transpl Rev (Orlando)2015;
29: 78–84.
49.
HusainANSiddiquiMTHolmesEW, et al.
Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med1999;
159: 829–833.
50.
RyanTPMorrisonRDSutherlandJJ, et al.
Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring. PLoS One2017;
12: e0185471.
51.
PabstSBertramAZimmermannT, et al.
Physician reported adherence to immunosuppressants in renal transplant patients: prevalence, agreement, and correlates. J Psychosom Res2015;
79: 364–371.
52.
BorraLCPRoodnatJIKalJA, et al.
High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transpl2010;
25: 2757–2763.
53.
RogalSSLandsittelDSurmanO, et al.
Pretransplant depression, antidepressant use, and outcomes of orthotopic liver transplantation. Liver Transpl2011;
17: 251–260.
54.
RogalSSDewMAFontesP, et al.
Early treatment of depressive symptoms and long-term survival after liver transplantation. Am J Transplant2013;
13: 928–935.
55.
Fusar-PoliPLazzarettiMCerutiM, et al.
Depression after lung transplantation: causes and treatment. Lung2007;
185: 55–65.
56.
DobbelsFDe BleserLBerbenL, et al.
Efficacy of a medication adherence enhancing intervention in transplantation: The MAESTRO-Tx trial. J Heart Lung Transpl2017;
36: 499–508.
57.
FinkelsteinSMSnyderMStibbeCE, et al.
Staging of bronchiolitis obliterans syndrome using home spirometry. Chest1999;
116: 120–126.
58.
KuglerCFuehnerTDierichM, et al.
Effect of adherence to home spirometry on bronchiolitis obliterans and graft survival after lung transplantation. Transplantation2009;
88: 129–134.
59.
Pollock-BarZivSMFinkelsteinYManlhiotC, et al.
Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transpl2010;
14: 968–975.
60.
Loghman-AdhamM.Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care2003;
9: 155–171.
61.
DobbelsFVanhaeckeJDupontL, et al.
Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation2009;
87: 1497–1504.
62.
NevinsTEThomasW.Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation2009;
87: 711–718.
63.
Saint-MarcouxFKnoopCDebordJ, et al.
Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling Strategies. Clin Pharmacokinet2005;
44: 1317–1328.
